Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of histone deacetylase inhibitor ITF2357 in relapsed/refractory chronic lymphocytic leukemia
2006-005465-19Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Italfarmaco. Primary endpoints: Rate of complete or partial response in all patients and Safety and tolerability. Started Jun 2007; status: terminated.
02
Drugs
givinostat
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-005465-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005465-19.